CFB and hyperuricemia: At a median follow-up of 60 days (IQR 44.5–60 days), 10 patients (9.0%) discontinued BA therapy due to musculoskeletal complaints (n = 4, 3.6%), gastrointestinal complaints (n = 3, 2.7%), or hyperuricemia (n = 3, 2.7%).